Brief: Pharma Mar Signs License Agreement With Lotus Pharmaceutical To Commercialize Lurbinectedin In Taiwan

Lotus Pharmaceutical

11/11/2021 07:39

Nov 11 (Reuters) - Pharma Mar SA  PHMR.MC :
    * ANNOUNCES SIGNATURE OF LICENSE AGREEMENT WITH LOTUS
PHARMACEUTICAL CO. LTD TO COMMERCIALIZE LURBINECTEDIN IN TAIWAN
    * UNDER AGREEMENT PHARMA MAR WILL RECEIVE NON-DISCLOSED
UPFRONT
PAYMENT AND WILL BE ELIGIBLE FOR ADDITIONAL REMUNERATIONS,
INCLUDING REGULATORY AND SALES MILESTONE PAYMENTS
    * WILL RETAIN PRODUCTION RIGHTS AND WILL SELL PRODUCT TO
LOTUS FOR
ITS CLINICAL AND COMMERCIAL USE
    * LOTUS WILL PURSUE MARKETING APPROVAL IN TAIWAN AND HAVE
RIGHT TO
MARKET PRODUCT EXCLUSIVELY UPON APPROVAL

Source text for Eikon:  ID:nCNM1h2NDM 
Further company coverage:  PHMR.MC 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))